• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

热休克蛋白 90 和信号转导子和转录激活子 3 在恶性嗜铬细胞瘤中的表达及诊断相关性。

Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma.

机构信息

Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

出版信息

J Clin Pathol. 2013 Apr;66(4):286-90. doi: 10.1136/jclinpath-2012-201134. Epub 2013 Jan 15.

DOI:10.1136/jclinpath-2012-201134
PMID:23322822
Abstract

BACKGROUND

Malignant pheochromocytoma (PCC) is a rare catecholamine producing tumour with a poor prognosis. For many years predicting PCC behaviour has remained a highly difficult task. The aim of this study was to evaluate heat shock protein 90 (HSP90) and signal transducer and activator of transcription 3 (STAT3) as tissue-based markers to predict malignant PCC.

METHODS

Ninety-two sporadic PCC patients were enrolled. We compared the expression of HSP90 and STAT3 by immunohistochemistry of benign versus malignant PCCs. In addition, in 17 snap frozen PCC and in 7 healthy adrenal tissues, we investigated the expression of HSP90 and STAT3 by means of western immunoblot.

RESULTS

Positive staining for HSP90 was observed in 22.37% (95% CI 13.00% to 31.74%) of the benign and 66.67% (95% CI 44.89% to 88.45%) of the malignant cases. Similarly, STAT3 staining was seen in 26.32% (95% CI 16.42% to 36.22%) of the benign versus 83.33% (95% CI 66.11% to 100.55%) of the malignant cases. Using HSP90 and STAT3 combined, the positive predictive value of malignancy was significantly increased to 0.70 (95% CI 0.45 to 0.86). Besides, logistic regression analysis showed that HSP90 (OR=3.667, p=0.039) and STAT3 (OR=9.474, p=0.002) were independently associated with malignant PCC.

CONCLUSIONS

This study has confirmed that malignant PCC overexpress HSP90 and STAT3, and the combination of HSP90 and STAT3 can be used as helpful diagnostic markers to distinguish malignant from benign PCCs.

摘要

背景

恶性嗜铬细胞瘤(PCC)是一种罕见的儿茶酚胺产生肿瘤,预后较差。多年来,预测 PCC 行为一直是一项极具挑战性的任务。本研究旨在评估热休克蛋白 90(HSP90)和信号转导和转录激活因子 3(STAT3)作为组织标志物,以预测恶性 PCC。

方法

纳入 92 例散发性 PCC 患者。我们比较了 HSP90 和 STAT3 的免疫组化表达,以区分良性和恶性 PCC。此外,在 17 例冰冻 PCC 和 7 例健康肾上腺组织中,我们通过 Western 免疫印迹法研究了 HSP90 和 STAT3 的表达。

结果

HSP90 阳性染色见于 22.37%(95%CI 13.00%至 31.74%)的良性病例和 66.67%(95%CI 44.89%至 88.45%)的恶性病例。同样,STAT3 染色见于 26.32%(95%CI 16.42%至 36.22%)的良性病例和 83.33%(95%CI 66.11%至 100.55%)的恶性病例。使用 HSP90 和 STAT3 联合检测,恶性肿瘤的阳性预测值显著增加至 0.70(95%CI 0.45 至 0.86)。此外,逻辑回归分析显示,HSP90(OR=3.667,p=0.039)和 STAT3(OR=9.474,p=0.002)与恶性 PCC 独立相关。

结论

本研究证实恶性 PCC 过度表达 HSP90 和 STAT3,HSP90 和 STAT3 的联合检测可作为鉴别良恶性 PCC 的有用诊断标志物。

相似文献

1
Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma.热休克蛋白 90 和信号转导子和转录激活子 3 在恶性嗜铬细胞瘤中的表达及诊断相关性。
J Clin Pathol. 2013 Apr;66(4):286-90. doi: 10.1136/jclinpath-2012-201134. Epub 2013 Jan 15.
2
[Pheochromocytoma--pathohistologic and immunohistochemical aspects].[嗜铬细胞瘤——病理组织学和免疫组织化学方面]
Srp Arh Celok Lek. 2002 Jul;130 Suppl 2:7-13.
3
A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma.基于组织微阵列的新型和传统免疫组织化学标志物在肾上腺皮质病变与嗜铬细胞瘤鉴别中的比较分析。
Am J Surg Pathol. 2010 Mar;34(3):423-32. doi: 10.1097/PAS.0b013e3181cfb506.
4
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.p53、bcl-2和c-erbB-2蛋白表达在嗜铬细胞瘤中的预后价值
J Pathol. 1999 May;188(1):51-5. doi: 10.1002/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R.
5
KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.KI-67和hTERT的表达有助于区分恶性和良性嗜铬细胞瘤及副神经节瘤。
Mod Pathol. 2003 Mar;16(3):246-55. doi: 10.1097/01.MP.0000056982.07160.E3.
6
Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry.激活素和抑制素亚基、受体及结合蛋白在人嗜铬细胞瘤中的表达:一项基于mRNA分析和免疫组织化学的研究
Clin Endocrinol (Oxf). 2007 Mar;66(3):335-40. doi: 10.1111/j.1365-2265.2007.02732.x.
7
Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.端粒复合体的表达谱可区分良性和恶性嗜铬细胞瘤。
J Clin Endocrinol Metab. 2003 Sep;88(9):4280-6. doi: 10.1210/jc.2002-021299.
8
STAT3 expression in gastric cancer indicates a poor prognosis.信号转导和转录激活因子3(STAT3)在胃癌中的表达提示预后不良。
J Gastroenterol Hepatol. 2009 Apr;24(4):646-51. doi: 10.1111/j.1440-1746.2008.05671.x. Epub 2008 Nov 3.
9
Role of miR-101 in pheochromocytoma patients with SDHD mutation.miR-101在携带SDHD突变的嗜铬细胞瘤患者中的作用。
Int J Clin Exp Pathol. 2015 Feb 1;8(2):1545-54. eCollection 2015.
10
Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.利用DNA流式细胞术和细胞增殖免疫组化标记物预测嗜铬细胞瘤转移:MIB-1染色与恶性肿瘤行为之间呈正相关。
Cancer. 1999 Oct 15;86(8):1583-9.

引用本文的文献

1
Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL).识别副神经节瘤转移潜能的预测因子以制定预后评分(PSPGL)。
J Endocr Soc. 2024 May 7;8(7):bvae093. doi: 10.1210/jendso/bvae093. eCollection 2024 May 23.
2
Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas.转移性副神经节瘤和嗜铬细胞瘤的潜在生物标志物。
Life (Basel). 2021 Nov 4;11(11):1179. doi: 10.3390/life11111179.
3
COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
COPPS 评分综合了病理特征、PS100 和 SDHB 缺失,可预测嗜铬细胞瘤/副神经节瘤的转移风险和无进展生存期。
Virchows Arch. 2019 Jun;474(6):721-734. doi: 10.1007/s00428-019-02553-5. Epub 2019 Mar 13.
4
NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo.新型热休克蛋白90(HSP90)抑制剂NVP - AUY922在体外和体内均能抑制恶性嗜铬细胞瘤的进展。
Onco Targets Ther. 2017 Apr 19;10:2219-2226. doi: 10.2147/OTT.S130236. eCollection 2017.
5
Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.嗜铬细胞瘤和副神经节瘤:诊断、遗传学、管理与治疗
Curr Probl Cancer. 2014 Jan-Feb;38(1):7-41. doi: 10.1016/j.currproblcancer.2014.01.001. Epub 2014 Jan 15.